Caprion-HistoGeneX and Viroclinics-DDL announce a strategic partnership to offer integrated, complementary services to advance infectious disease research and COVID-19 therapeutic development.
Viroclinics Biosciences B.V. (“Viroclinics”) today announced the appointment of life sciences industry veteran Davide Molho, DVM as the company’s new Chief Executive Officer. Dr. Molho succeeds Bob van Gemen, PhD who has served as the company’s CEO since 2011. This transition is part of a planned succession strategy. Dr. Molho’s appointment will take effect on 1 August 2020.
9 April 2020 The University of Queensland’s potential COVID-19 vaccine is entering an important new phase of testing with the live coronavirus to determine how effectively it induces protection against coronavirus infection. The UQ team will partner with the Dutch...
Preceding weeks have made clear that COVID-19 continues to spread and is paralyzing the world. Times are unprecedented and show us how vulnerable we are and how we depend on each other. As a service organization – highly specialized in virology – we will commit ourselves to realign our resources, equipment and materials to new initiatives to test anti-virals, immune modulators and vaccines in the battle against COVID-19.
Global growth equity investor Summit Partners today announced a majority investment in Viroclinics Biosciences B.V., a leading specialized contract research organization (CRO) serving the global biopharmaceutical industry. The funding will be used to fuel continued expansion of Viroclinics’ services, capacity and international presence.
Subscribe to our newsletter for the latest insights on early stage, (pre)clinical research, cold chain logistics and assay development services.